BridgeBio prices secondary offering of 5 million shares by KKR Genetic Disorder LP
BBIO•Secondary offering priced at oversubscribed level
- BridgeBio priced an oversubscribed secondary offering of 5,000,000 common shares sold by KKR Genetic Disorder L.P.
- No shares were sold by BridgeBio, and the company will receive no proceeds from the offering.
- The offering is expected to close Aug. 17, 2026, subject to customary closing conditions.
- William Blair, Goldman Sachs and KKR Capital Markets are acting as joint book-running managers.
Related News
Tencent grants 1,952,440 employee share options at HKD 466.72 each
TCEHY•
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
LTRN•
